XML 24 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Balance Sheet Details
 3 Months Ended
Mar. 31, 2024
Other Balance Sheet Details [Abstract]  
Other Balance Sheet Details Other Balance Sheet Details
Inventory consisted of the following:
(in millions)March 31,
2024		December 31,
2023
Raw materials$18.1 $21.5 
Work in process12.0 9.7 
Finished goods7.5 12.3 
37.6 43.5 
Less inventory reserves
(0.4)(5.2)
Total inventory
$37.2 $38.3 
Accounts payable and accrued liabilities consisted of the following:
(in millions)March 31,
2024		December 31,
2023
Sales rebates and reserves$185.9 $139.3 
Accrued employee related costs42.6 86.2 
Current branded prescription drug fee35.3 45.7 
Accrued development costs41.3 44.3 
Current income taxes payable
24.8 24.4 
Accounts payable and other accrued liabilities87.3 108.9 
Total accounts payable and accrued liabilities$417.2 $448.8 
Other noncurrent liabilities consisted of the following:
(in millions)March 31,
2024		December 31,
2023
Noncurrent income taxes payable
$101.1 $96.0 
Noncurrent branded prescription drug fee
19.4 10.3 
Total other noncurrent liabilities$120.5 $106.3 
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows.
(in millions)March 31,
2024		March 31,
2023
Cash and cash equivalents$396.3 $103.8 
Restricted cash included in other noncurrent assets
8.0 7.8 
Total cash, cash equivalents and restricted cash$404.3 $111.6